Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company is developing modified immune system cells programmed to sense and respond to cancer cells…
    about 11 hours ago
  • New post on Science and Enterprise: T-Cells Engineered to Release Anti-Cancer Proteins #Science #Business
    about 11 hours ago
  • An engineering team designed a process for adding and protecting tiny particles of nutrients in foods, boosting the…
    about 13 hours ago
  • New post on Science and Enterprise: Polymer-Coated Microparticles Boost Food Nutrition #Science #Business
    about 13 hours ago
  • New contributed post on Science and Enterprise: How To Avoid Lapses In Productivity
    about 18 hours ago

Please share Science & Enterprise

Luminex Corp. Acquires Molecular Diagnostics Developer

DNA strand (


Luminex Corporation, a maker of medical diagnostics technologies in Austin, Texas will acquire Hayward, California-based GenturaDx, a developer of genomic testing systems. The $50 million deal involves Luminex purchasing all outstanding shares in the privately-owned GenturaDx.

Luminex develops and manufactures instruments, software, reagents, and assays used in clinical labs as well as in pharmaceutical, diagnostic, and biotechnology businesses. The company’s product line includes real-time polymerase chain reaction (PCR) testing technologies for clinical and research labs. PCR is an method for analyzing short sequences of DNA or RNA, which can be applied to even minute samples. PCR is used to amplify selected sections of DNA or RNA.

GenturaDx is in late-stage development of an automated bench-top PCR testing instrument called the IDbox that it says integrates the entire process from sample preparation through amplification and detection to reporting out results. The IDbox uses GenturaDx’s closed, single-use cassette that contains all of the required testing reagents for a PCR test, and can report on multiple analytes in one pass.

Luminex says it plans to integrate the two technologies into one system for molecular diagnostic testing. The company anticipates commercial availability of a variety of assays for use with this system by early 2014. The acquisition is expected to add some $6 million to Luminex’s operating expenses in 2012.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.